{"id":"https://openalex.org/W2067104263","doi":"https://doi.org/10.1002/phar.1507","title":"GLP \u20101 Receptor Agonists for Type 2 Diabetes Mellitus: Recent Developments and Emerging Agents","display_name":"GLP \u20101 Receptor Agonists for Type 2 Diabetes Mellitus: Recent Developments and Emerging Agents","alternate_titles":[],"publication_year":2014,"publication_date":"2014-11-01","ids":{"openalex":"https://openalex.org/W2067104263","doi":"https://doi.org/10.1002/phar.1507","mag":"2067104263","pmid":"https://pubmed.ncbi.nlm.nih.gov/25382096"},"language":"en","primary_location":{"id":"doi:10.1002/phar.1507","doi":"https://doi.org/10.1002/phar.1507","is_oa":false,"landing_page_url":"https://doi.org/10.1002/phar.1507","pdf_url":null,"source":{"id":"https://openalex.org/S122731057","display_name":"Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy","issn_l":"0277-0008","issn":["0277-0008","1875-9114"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-c","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-100","russia-white-list-1"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy","raw_type":"journal-article"},"parent_works":[],"lineage":["https://openalex.org/W2067104263"],"child_works_count":0,"type":"review","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5054620018","display_name":"Jennifer M. Trujillo","orcid":"https://orcid.org/0000-0001-7898-8029","observed_orcids":["https://orcid.org/0000-0001-7898-8029"]},"institutions":[],"countries":[],"is_corresponding":true,"raw_author_name":"Jennifer M. Trujillo","raw_affiliation_strings":["University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences Aurora Colorado","University of Colorado, Skaggs School of Pharmacy & Pharmaceutical Sciences, Aurora, Colorado"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences Aurora Colorado","institution_ids":[]},{"raw_affiliation_string":"University of Colorado, Skaggs School of Pharmacy & Pharmaceutical Sciences, Aurora, Colorado","institution_ids":[]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5016624558","display_name":"Wesley A. Nuffer","orcid":"https://orcid.org/0000-0002-3355-4582","observed_orcids":["https://orcid.org/0000-0002-3355-4582"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Wesley Nuffer","raw_affiliation_strings":["University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences Aurora Colorado","University of Colorado, Skaggs School of Pharmacy & Pharmaceutical Sciences, Aurora, Colorado"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences Aurora Colorado","institution_ids":[]},{"raw_affiliation_string":"University of Colorado, Skaggs School of Pharmacy & Pharmaceutical Sciences, Aurora, Colorado","institution_ids":[]}]}],"institutions":[],"countries_distinct_count":0,"institutions_distinct_count":0,"corresponding_author_ids":["https://openalex.org/A5054620018"],"corresponding_institution_ids":[],"apc_list":{"value":4030,"currency":"USD","value_usd":4030},"apc_paid":null,"fwci":1.3405,"has_fulltext":false,"cited_by_count":102,"citation_normalized_percentile":{"value":0.79050155,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":95,"max":99},"biblio":{"volume":"34","issue":"11","first_page":"1174","last_page":"1186"},"is_retracted":false,"is_pulled":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10401","display_name":"Diabetes Treatment and Management","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2712","display_name":"Endocrinology, Diabetes and Metabolism"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10401","display_name":"Diabetes Treatment and Management","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2712","display_name":"Endocrinology, Diabetes and Metabolism"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10560","display_name":"Diabetes Management and Research","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2712","display_name":"Endocrinology, Diabetes and Metabolism"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T12539","display_name":"Pharmacology and Obesity Treatment","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2736","display_name":"Pharmacology (medical)"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/glp-1-receptor-agonists","display_name":"GLP-1 receptor agonists","score":0.9290000200271606},{"id":"https://openalex.org/keywords/type-2-diabetes","display_name":"type 2 diabetes","score":0.9990000128746033},{"id":"https://openalex.org/keywords/glycemic-control","display_name":"glycemic control","score":0.9819999933242798},{"id":"https://openalex.org/keywords/lixisenatide","display_name":"lixisenatide","score":0.8370000123977661},{"id":"https://openalex.org/keywords/albiglutide","display_name":"albiglutide","score":0.9990000128746033},{"id":"https://openalex.org/keywords/dulaglutide","display_name":"dulaglutide","score":1.0},{"id":"https://openalex.org/keywords/weight-loss","display_name":"weight loss","score":0.9369999766349792},{"id":"https://openalex.org/keywords/gastrointestinal-side-effects","display_name":"gastrointestinal adverse effects","score":0.9020000100135803},{"id":"https://openalex.org/keywords/pharmacokinetics","display_name":"pharmacokinetics","score":0.8230000138282776}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8903003931045532},{"id":"https://openalex.org/C2780473172","wikidata":"https://www.wikidata.org/wiki/Q5572518","display_name":"Glycemic","level":3,"score":0.6404419541358948},{"id":"https://openalex.org/C2779829264","wikidata":"https://www.wikidata.org/wiki/Q21011228","display_name":"Dulaglutide","level":5,"score":0.6354466676712036},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.6117550730705261},{"id":"https://openalex.org/C2777180221","wikidata":"https://www.wikidata.org/wiki/Q3025883","display_name":"Type 2 diabetes","level":3,"score":0.5828822255134583},{"id":"https://openalex.org/C2781308992","wikidata":"https://www.wikidata.org/wiki/Q2526479","display_name":"Liraglutide","level":4,"score":0.5765082240104675},{"id":"https://openalex.org/C2780668416","wikidata":"https://www.wikidata.org/wiki/Q202758","display_name":"Hypoglycemia","level":3,"score":0.5544704794883728},{"id":"https://openalex.org/C2780533449","wikidata":"https://www.wikidata.org/wiki/Q417762","display_name":"Exenatide","level":4,"score":0.5265536308288574},{"id":"https://openalex.org/C185280430","wikidata":"https://www.wikidata.org/wiki/Q14909910","display_name":"Glucagon-like peptide 1 receptor","level":4,"score":0.5085424184799194},{"id":"https://openalex.org/C2910068830","wikidata":"https://www.wikidata.org/wiki/Q3025883","display_name":"Type 2 Diabetes Mellitus","level":3,"score":0.4927504360675812},{"id":"https://openalex.org/C2779306644","wikidata":"https://www.wikidata.org/wiki/Q2002370","display_name":"Insulin","level":2,"score":0.49237263202667236},{"id":"https://openalex.org/C2778199505","wikidata":"https://www.wikidata.org/wiki/Q2992990","display_name":"Postprandial","level":3,"score":0.47070762515068054},{"id":"https://openalex.org/C555293320","wikidata":"https://www.wikidata.org/wiki/Q12206","display_name":"Diabetes mellitus","level":2,"score":0.4602659046649933},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.38148507475852966},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.3675495684146881},{"id":"https://openalex.org/C134018914","wikidata":"https://www.wikidata.org/wiki/Q162606","display_name":"Endocrinology","level":1,"score":0.2952319383621216},{"id":"https://openalex.org/C170493617","wikidata":"https://www.wikidata.org/wiki/Q208467","display_name":"Receptor","level":2,"score":0.09139469265937805},{"id":"https://openalex.org/C2778938600","wikidata":"https://www.wikidata.org/wiki/Q389934","display_name":"Agonist","level":3,"score":0.08612051606178284}],"mesh":[{"descriptor_ui":"D000067757","descriptor_name":"Glucagon-Like Peptide-1 Receptor","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000067758","descriptor_name":"Glucagon-Like Peptide-2 Receptor","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D003924","descriptor_name":"Diabetes Mellitus, Type 2","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D003924","descriptor_name":"Diabetes Mellitus, Type 2","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D004334","descriptor_name":"Drug Administration Schedule","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D004359","descriptor_name":"Drug Therapy, Combination","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D004763","descriptor_name":"Glucagon-Like Peptides","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D004763","descriptor_name":"Glucagon-Like Peptides","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D004763","descriptor_name":"Glucagon-Like Peptides","qualifier_ui":"Q000031","qualifier_name":"analogs & derivatives","is_major_topic":false},{"descriptor_ui":"D004763","descriptor_name":"Glucagon-Like Peptides","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006943","descriptor_name":"Hyperglycemia","qualifier_ui":"Q000517","qualifier_name":"prevention & control","is_major_topic":true},{"descriptor_ui":"D007003","descriptor_name":"Hypoglycemia","qualifier_ui":"Q000139","qualifier_name":"chemically induced","is_major_topic":false},{"descriptor_ui":"D007003","descriptor_name":"Hypoglycemia","qualifier_ui":"Q000517","qualifier_name":"prevention & control","is_major_topic":true},{"descriptor_ui":"D007004","descriptor_name":"Hypoglycemic Agents","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D007004","descriptor_name":"Hypoglycemic Agents","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D007004","descriptor_name":"Hypoglycemic Agents","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D007141","descriptor_name":"Immunoglobulin Fc Fragments","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D007141","descriptor_name":"Immunoglobulin Fc Fragments","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D007141","descriptor_name":"Immunoglobulin Fc Fragments","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D007279","descriptor_name":"Injections, Subcutaneous","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D007328","descriptor_name":"Insulin","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D007328","descriptor_name":"Insulin","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D010455","descriptor_name":"Peptides","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D010455","descriptor_name":"Peptides","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D010455","descriptor_name":"Peptides","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D011993","descriptor_name":"Recombinant Fusion Proteins","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D011993","descriptor_name":"Recombinant Fusion Proteins","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D011993","descriptor_name":"Recombinant Fusion Proteins","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D015431","descriptor_name":"Weight Loss","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":false},{"descriptor_ui":"D015507","descriptor_name":"Drugs, Investigational","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D015507","descriptor_name":"Drugs, Investigational","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D015507","descriptor_name":"Drugs, Investigational","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D018027","descriptor_name":"Receptors, Glucagon","qualifier_ui":"Q000037","qualifier_name":"antagonists & inhibitors","is_major_topic":true},{"descriptor_ui":"D018027","descriptor_name":"Receptors, Glucagon","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D019440","descriptor_name":"Anti-Obesity Agents","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D019440","descriptor_name":"Anti-Obesity Agents","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D052216","descriptor_name":"Glucagon-Like Peptide 1","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D052216","descriptor_name":"Glucagon-Like Peptide 1","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D052216","descriptor_name":"Glucagon-Like Peptide 1","qualifier_ui":"Q000031","qualifier_name":"analogs & derivatives","is_major_topic":false},{"descriptor_ui":"D052216","descriptor_name":"Glucagon-Like Peptide 1","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false}],"locations_count":2,"locations":[{"id":"doi:10.1002/phar.1507","doi":"https://doi.org/10.1002/phar.1507","is_oa":false,"landing_page_url":"https://doi.org/10.1002/phar.1507","pdf_url":null,"source":{"id":"https://openalex.org/S122731057","display_name":"Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy","issn_l":"0277-0008","issn":["0277-0008","1875-9114"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-c","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-100","russia-white-list-1"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy","raw_type":"journal-article"},{"id":"pmid:25382096","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/25382096","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Pharmacotherapy","raw_type":"Journal Article"}],"best_oa_location":null,"sustainable_development_goals":[{"score":0.9940000176429749,"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":47,"referenced_works":["https://openalex.org/W47631135","https://openalex.org/W1533461932","https://openalex.org/W1584571461","https://openalex.org/W1975929001","https://openalex.org/W1977102586","https://openalex.org/W1978470174","https://openalex.org/W2002057113","https://openalex.org/W2002401619","https://openalex.org/W2002757015","https://openalex.org/W2003415509","https://openalex.org/W2013082477","https://openalex.org/W2015788437","https://openalex.org/W2019513002","https://openalex.org/W2030546890","https://openalex.org/W2054568668","https://openalex.org/W2054981500","https://openalex.org/W2060420423","https://openalex.org/W2061883499","https://openalex.org/W2077751509","https://openalex.org/W2090054860","https://openalex.org/W2101613382","https://openalex.org/W2102400698","https://openalex.org/W2104252114","https://openalex.org/W2104788765","https://openalex.org/W2106709036","https://openalex.org/W2106824929","https://openalex.org/W2108122035","https://openalex.org/W2108472697","https://openalex.org/W2111876001","https://openalex.org/W2114027444","https://openalex.org/W2124831863","https://openalex.org/W2128825255","https://openalex.org/W2133648480","https://openalex.org/W2135064706","https://openalex.org/W2137562839","https://openalex.org/W2138077952","https://openalex.org/W2143996444","https://openalex.org/W2147091345","https://openalex.org/W2154433510","https://openalex.org/W2162661457","https://openalex.org/W2163387116","https://openalex.org/W2170606300","https://openalex.org/W2936187128","https://openalex.org/W6650888494","https://openalex.org/W6665673096","https://openalex.org/W6678842497","https://openalex.org/W6761700673"],"related_works":["https://openalex.org/W2123041020","https://openalex.org/W1753769072","https://openalex.org/W2220690107","https://openalex.org/W2277023506","https://openalex.org/W2963614034","https://openalex.org/W2765093610","https://openalex.org/W2943788927","https://openalex.org/W2023891261","https://openalex.org/W2889552513","https://openalex.org/W2889521172"],"abstract_inverted_index":{"More":[0],"than":[1],"26":[2],"million":[3],"people":[4],"in":[5,24,98,125,130,138,153,223,259],"the":[6,61,91,101,212,221,234],"United":[7],"States":[8],"have":[9,55],"type":[10,139],"2":[11],"diabetes":[12],"mellitus":[13],"(T2D).":[14],"Many":[15],"treatment":[16,39,62,251,261],"options":[17,59,252],"exist,":[18],"but":[19,211],"achieving":[20],"long-term":[21],"glycemic":[22,43],"control":[23,44],"patients":[25],"with":[26,48,132],"T2D":[27,254],"remains":[28],"challenging.":[29],"The":[30,194,244],"glucagon-like":[31],"peptide-1":[32],"receptor":[33],"agonists":[34],"(GLP-1":[35],"RAs)":[36],"offer":[37,190],"a":[38,49,88,157],"option":[40],"that":[41,161,188],"improves":[42],"and":[45,65,68,103,114,142,165,182,209,230],"reduces":[46],"weight,":[47],"low":[50],"risk":[51],"of":[52,63,90,105,111,117,199,214,227,246],"hypoglycemia.":[53],"They":[54],"emerged":[56],"as":[57,135,175,255,257],"attractive":[58],"for":[60,143,253],"T2D,":[64],"significant":[66],"advances":[67],"developments":[69],"continue":[70],"to":[71,85,172,178,220],"be":[72,167,241],"published":[73,97],"regarding":[74],"these":[75],"agents.":[76,218],"To":[77],"identify":[78],"relevant":[79],"literature":[80],"on":[81],"emerging":[82,151],"issues":[83],"related":[84],"GLP-1":[86,106,119,159,186,201,235,247],"RAs,":[87],"search":[89],"MEDLINE":[92],"database":[93],"was":[94],"performed.":[95],"Studies":[96],"English":[99],"evaluating":[100],"safety":[102],"efficacy":[104],"RAs":[107,120,187,248],"were":[108],"analyzed.":[109],"Because":[110],"their":[112],"advantages":[113],"unique":[115],"mechanism":[116],"action,":[118],"are":[121,149,184,204],"currently":[122],"being":[123],"studied":[124],"new":[126],"clinical":[127],"areas,":[128],"including":[129],"combination":[131],"basal":[133,173],"insulin,":[134],"adjunctive":[136],"therapy":[137],"1":[140],"diabetes,":[141],"weight":[144],"loss.":[145],"In":[146],"addition,":[147],"there":[148],"several":[150],"agents":[152,203],"development.":[154],"Lixisenatide":[155],"is":[156],"once-daily":[158],"RA":[160,202,236],"targets":[162],"postprandial":[163],"glucose":[164],"may":[166,189],"most":[168,195],"useful":[169],"when":[170],"added":[171],"insulin":[174],"an":[176],"alternative":[177],"rapid-acting":[179],"insulin.":[180],"Albiglutide":[181],"dulaglutide":[183],"once-weekly":[185],"more":[191],"convenient":[192],"dosing.":[193],"common":[196],"adverse":[197,228],"effects":[198],"all":[200],"gastrointestinal":[205],"(e.g.,":[206],"nausea,":[207],"diarrhea,":[208],"vomiting),":[210],"rates":[213,226],"occurrence":[215],"vary":[216],"among":[217],"Due":[219],"differences":[222],"pharmacokinetics,":[224],"efficacy,":[225],"effects,":[229],"administration":[231],"requirements":[232],"within":[233],"class,":[237],"each":[238],"agent":[239],"should":[240],"evaluated":[242],"independently.":[243],"future":[245],"offers":[249],"broader":[250],"well":[256],"potential":[258],"other":[260],"areas.":[262]},"cited_by_api_url":"https://api.openalex.org/works?filter=cites:W2067104263","counts_by_year":[{"year":2026,"cited_by_count":7},{"year":2025,"cited_by_count":10},{"year":2024,"cited_by_count":6},{"year":2023,"cited_by_count":4},{"year":2022,"cited_by_count":10},{"year":2021,"cited_by_count":3},{"year":2020,"cited_by_count":12},{"year":2019,"cited_by_count":7},{"year":2018,"cited_by_count":11},{"year":2017,"cited_by_count":13},{"year":2016,"cited_by_count":8},{"year":2015,"cited_by_count":11}],"updated_date":"2026-11-16T12:05:36.265796","created_date":"2016-06-24T00:00:00"}
